Kazia Therapeutics doses first patient in paediatric brain cancer trial
Kazia Therapeutics initiated dosing in its PNOC035 clinical study evaluating drug candidate paxalisib alongside gemcitabine for children and young adults with recurrent AT RT brain cancer
We haven't written up this one. Vietnam Investment Review has the full story — the link below goes straight to it.